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Summary
Linkage disequilibrium (LD) testing has become a pop-
ular and effective method of fine-scale disease-gene lo-
calization. It has been proposed that LD testing could
also be used for genome screening, particularly as dense
maps of diallelic markers become available and auto-
mation allows inexpensive genotyping of diallelic mark-
ers. We compare diallelic markers and multiallelic mark-
ers in terms of sample sizes required for detection of LD,
by use of a single marker locus in a case-control study,
for rare monophyletic diseases with Mendelian inheri-
tance. We extrapolate from our results to discuss the
feasibility of single-marker LD screening in more-com-
plex situations. We have used a deterministic population
genetic model to calculate the expected power to detect
LD as a function of marker density, age of mutation,
number of marker alleles, mode of inheritance of a rare
disease, and sample size. Our calculations show that
multiallelic markers always have more power to detect
LD than do diallelic markers (under otherwise equiva-
lent conditions) and that the ratio of the number of
diallelic to the number of multiallelic markers needed
for equivalent power increases with mutation age and
complexity of mode of inheritance. Power equivalent to
that achieved by a multiallelic screen can theoretically
be achieved by use of a more dense diallelic screen, but
mapping panels of the necessary resolution are not cur-
rently available and may be difficult to achieve. Genome
screening that uses single-marker LD testing may there-
fore be feasible only for young (!20 generations), rare,
monophyletic Mendelian diseases, such as may be found
in rapidly growing genetic isolates.
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Introduction
Under certain assumptions about population history,
linkage disequilibrium (LD) between a marker locus and
a disease locus is believed to indicate that the two loci
are closely linked (Briscoe et al. 1994; Plomin et al. 1994;
Jorde 1995; Kaplan et al. 1995). The first instance of a
disease-causing mutation must necessarily occur on a
particular background haplotype. The disease allele is
then associated with the alleles carried at other loci on
that same haplotype. This association, or LD, is reduced
over time (measured in generations) as recombinations
occur between the disease locus and linked loci, and the
rate of decay of LD is related to the recombination frac-
tion between the disease locus and the locus of interest.
For tightly linked loci, recombination events are rare,
and LD will therefore remain strong for many genera-
tions, whereas for larger recombination fractions LDwill
decay more rapidly. These principles suggest the use of
LD testing as a tool for disease-gene localization.
There are two distinct but related situations in which
the use of LD to localize disease loci is of interest. First,
there is the case in which traditional meiotic mapping
techniques have mapped the gene of interest to a par-
ticular region of a chromosome. One possible approach
at this point is to collect more family data to refine the
location of the disease locus by meiotic methods. How-
ever, the disadvantage of this approach is the prohibi-
tively large sample sizes needed to narrow the regions
sufficiently to embark on gene identification studies
(Boehnke 1994). Collection of a sufficiently large col-
lection of families may be impossible, especially for re-
cessive diseases. Even when large samples of appropriate
pedigrees could, in principle, be obtained, the associated
sampling and genotyping costs may far exceed those of
a case-control study based on LD testing. Amajor reason
for this difference in cost is that both theoretical argu-
ments and empirical evidence suggest that strong LD
with a disease locus is usually confined to an interval of
!2 cM—and, often, much less (Thompson and Neel
1997; Wijsman 1997). Sample sizes necessary to detect
such LD by use of a diallelic marker are generally rel-
atively modest (Olson and Wijsman 1994). Because of
these practical considerations of feasibility and cost, LD
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testing following initial meiotic mapping of a gene has
become a popular approach, and there are numerous
examples of its success in narrowing the regions con-
taining disease loci (e.g., see Ha¨stbacka et al. 1992;Mac-
Donald et al. 1992; Ellis et al. 1994; Goddard et al.
1996; Votruba et al. 1997).
A second use of LD testing is in the context of an
initial genome screen for a disease locus of interest. The
increasing density of markers available for mapping,
coupled with the increasing automation of genotyping,
suggests that genome screening that uses LD testing may
soon be a feasible method of disease-gene localization
in isolated populations (Houwen et al. 1994), in selected
hybrid populations (Briscoe et al. 1994; Shriver et al.
1997), and perhaps even in large randomly mating pop-
ulations (Risch and Merikangas 1996; Brown and Hart-
well 1998). Genome screens for LD recently have been
used by Hovatta et al. (1997), to find regions of interest
in the search for a schizophrenia gene in a recent internal
isolate of the Finnish population, and by Escamilla et
al. (1996), to search for genes for bipolar disorder in a
Costa Rican population.
If LD testing is to be used for disease-gene localization
in either of the aforementioned situations, a method of
approximating its power—and, therefore, determining
the required sample size—is necessary. Sample size issues
have previously been explored for single-marker LD test-
ing both for population-based (Thompson et al. 1988)
and case-control (Olson andWijsman 1994) designs, but
only for diallelic markers. Restriction of previous studies
to diallelic markers is largely a result of the ease with
which a single measure of disequilibrium can be de-
fined—a single parameter allows description of the dis-
tribution of the test statistic under various levels of dis-
equilibrium, leading to expressions that can be used for
statistical power and sample size estimation.
Although sample size issues have been explored for
diallelic markers, most applications of LD testing cur-
rently involve multiallelic markers. The approach most
commonly implemented is to collapse alleles, effectively
creating a diallelic marker, and then perform LD testing
in the usual way. Unfortunately, this collapsing is often
either data based or completely arbitrary and can result
in both type I and type II errors (Weir and Cockerham
1978; Goddard et al. 1996). Sham and Curtis (1995)
considered Monte Carlo association tests that either
combined alleles or considered each allele in turn against
the rest and found that the power to detect association
was reduced when there were many marker alleles. In
fact, it is not necessary to reduce the problem to one
involving a diallelic marker. For an m-allele marker, one
can test for LD by using either a x2 test, with df,m 1
or, when data are sparse, by Fisher’s exact test. Although
there is no single measure of disequilibrium in this case,
there does exist a single measure of association (Kaplan
et al. 1997) that can be used to estimate statistical power
to detect association (Ott and Rabinowitz 1997).
Given that markers with two or more alleles can be
used in LD testing, it is also of interest to determine
what types of markers and screening panels provide the
most power to detect LD. In particular, how do mul-
tiallelic markers such as microsatellite markers (Weber
and May 1989) compare with diallelic markers, such
as single-nucleotide polymorphisms (Nickerson et al.
1992)? This question has become particularly timely as
automated and inexpensive genotyping methods have
become available for diallelic loci (see, e.g., Chee et al.
1996). The answer to this question is not immediately
obvious. Although multiallelic markers will be more
polymorphic—and, therefore, more informative—than
diallelic markers, an increase in the number of alleles
results in an increase in the df of the test statistic, which
can result in a loss of power to detect association.
In the present report, we present information crucial
to the design of effective studies to screen for markers
demonstrating LD with a disease locus. We compare
diallelic markers to multiallelic markers, in terms of sam-
ple sizes required for detection of LD, by use of single-
marker tests, and find that multiallelic markers are al-
most always superior. We also describe relative marker
spacings necessary for diallelic and multiallelic markers
to achieve similar power. Finally, we describe the Men-
delian genetic models and population histories under
which LD can be detected by use of reasonable sample
sizes and marker densities.
Methods
We consider a typical case-control study design, in
which marker allele frequencies on chromosomes carried
by affected individuals are compared with marker allele
frequencies on chromosomes carried by unaffected in-
dividuals. We first describe an appropriate test statistic
and its asymptotic distributions in the presence and ab-
sence of LD. We then discuss the parameters necessary
to approximate the power, and we describe power cal-
culations for a rare recessive disease. We generalize the
results for a dominant disease, and, finally, we discuss
the parameter values used in our population genetic
model.
Test Statistic
Consider the design in which n cases and an equal
number of controls are sampled. Olson and Wijsman
(1994) showed that, for a diallelic marker, power is al-
ways maximized for a given total sample size when equal
numbers of cases and controls are considered. Since this
aspect of the study design is under the control of the
experimenter, we do not consider other partitions of the
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Table 1
Configuration of Haplotype Frequencies at the Time of Initial
Mutation ( )t  0
MARKER LOCUS
DISEASE LOCUS
Mutation Normal Total
Allele i r s  ri si
Allele j ( ; )j  1,) ,m j ( i 0 sj sj
Total r 1 r 1
total sample size. For this case, the data can be described
in a table, where m is the number of marker2#m
alleles. One can define a x2 statistic to test the null hy-
pothesis that the marker allele frequencies in the two
groups are equal, as follows:
2(observed expected)2X  
expectedall cells
m 2
ˆ ˆ(p  q )i i 2n ,
ˆ ˆp  qi1 i i
where and represent the observed marker allele fre-ˆ ˆp q
quencies in the case individuals and control individuals,
respectively, and n is the number of cases sampled.
Under the null hypothesis of equal marker allele fre-
quencies, X2 is asymptotically distributed as . An2xm1
a-level test therefore rejects the null hypothesis when
. Under the alternative of unequal marker2 2X  xm1,1a
allele frequencies (i.e., LD), X2 is asymptotically dis-
tributed as , where2 m 2x (g) g  2n [(p  q ) / (p m1 i1 i i i
. Therefore, the asymptotic power of the test2q )] { 2nGi
at level a is given by , which is2 2Pr[x (g)  x ]m1 m1,1a
easily obtained from standard statistical software, given
values of n, m, a, and G2.
It is interesting to note that the noncentrality param-
eter is monotone increasing in G2, which is a genetic
distance measure proposed by Balakrishnan and Sanghvi
(1968). LD testing is therefore equivalent to testing the
hypothesis that this genetic distance is zero. G2 can be
thought of as a weighted version of the Euclidean dis-
tance between the vectors p and q, and therefore it is
expected to increase as the dimensionality (i.e., m, the
number of marker alleles) of vectors p and q increases.
If the df of the test were to remain constant, this would
result in an increase in power with an increase in the
number of alleles. However, as the number of marker
alleles increases, so does the df of the test. This will
counteract, to some extent, the increase inG2, and, thus,
the impact of the use of multiallelic markers on power
to detect LD is not immediately apparent.
Computation of G2
The parameters of the power calculation are easily
specified, with the exception of G2, which depends on
the population history. To calculate G2, we assumed a
deterministic population genetic model in which a single
mutation was introduced into the population t genera-
tions ago, with a frequency of r. This could have oc-
curred either by spontaneous mutation or by the im-
migration of an individual carrying the mutation
(founder effect). We will refer to this time t as the age
of the mutation. Initial disequilibrium was assumed to
be complete—that is, all the initial mutations happened
on the same chromosomal background. The configu-
ration of haplotype frequencies at the time of initial mu-
tation ( ) can then be described as in table 1, wheret  0
the vector s denotes the marker allele frequencies at the
time of the initial mutation and the initial mutation is
assumed to occur on a background of allele i.
We further assumed nonoverlapping generations, ran-
dom mating, no migration, no subsequent mutation at
the disease or marker locus, no genetic drift, and that
the overall population frequencies of the marker alleles
and the disease mutation remained constant. These as-
sumptions are the same as those used by Devlin and
Risch (1995) and Devlin et al. (1996), except that they
considered a growing population and allowed genetic
drift. Our results therefore reflect the expectation forG2
over all possible drift histories. Under these assumptions,
the population frequency, at time t, of chromosomes
carrying the disease mutation d and marker allele j
( ) is given by(t)p , j  1,) ,mj,d
(t) tp  rs  (1 v) (rs ), j  1,) ,m, j ( ij,d j j
t [1 (1 v) ]rs (1)j
and
(t) tp  rs  (1 v) (r rs )i,d i i
t t [1 (1 v) ]rs  (1 v) r . (2)i
Equation (1) expresses the frequency of haplotypes car-
rying both the disease mutation and marker allele j as
the expected frequency if there were no LD, plus the
initial disequilibrium, which has decayed over time. Al-
ternatively, it can be expressed as the probability that a
chromosome carrying the disease mutation has recom-
bined with a normal chromosome carrying allele j at the
marker locus. Similarly, equation (2) expresses the fre-
quency of haplotypes carrying both the disease mutation
and marker allele j as the expected frequency if there
were no LD, adjusted for the remaining LD, or, alter-
natively, as the probability that no recombinations oc-
curred, plus the probability that a recombination did
occur but with a chromosome carrying allele i. If we let
the vectors x and y represent the marker allele frequen-
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cies in the disease mutation–carrying chromosomes and
the normal chromosomes, respectively, we can write
(t) t[ ]x  s 1 (1 v) ,j j
r(t) ty  s 1 (1 v) ,j j [ ]1 r
j  1,) ,m, j ( i
and
(t) tx  s  (1 s )(1 v) ,i i i
r(t) ty  s  (1 s )(1 v) .i i i1 r
To calculate the quantity of interest —that is, the2G (t)i
expected value ofG2(t), given that the mutation occurred
on a background of allele i—we must obtain p and q,
the marker allele frequencies in affected and unaffected
individuals, respectively. Each of these quantities will be
a weighted average of x and y, with the weights deter-
mined by the mode of inheritance of the disease. For a
rare recessive disease, p is equal to x and q is approx-
imately equal to y. The quantity is easily calculated2G (t)i
from p and q. If we assume that marker polymorphism
preceded the disease mutation, the probability that the
mutation happened on a background of allele i is simply
si. The expected value ofG
2(t) is then a weighted average
of the conditional expected values: .2 m 2G (t)  S sG (t)i1 i i
Dominant versus Recessive Diseases
For a fully penetrant rare dominant disease, p is ap-
proximately the average of x and y, because most cases
will be heterozygous for the mutation, and q is equal to
y. Thus G2 is easily calculated for rare dominant dis-
eases, too. It is also instructive to consider the following
relationship between recessive and dominant diseases:
for a rare mutation, where , . If the(t)r/ (1 r)  0 y  s
disease is caused by a recessive mutation generationstr
old,
(t ) (t ) (t )r r rp  x and q  s ; (3)
for a rare dominant disease that is generations old,td
1 1(t ) (t ) (t )d d dp  x  s and q  s . (4)
2 2
Now, if , the value of G2 for the two different(t ) (t )d rp  p
situations would be the same. By setting and(t ) (t )d rp  p
solving for tr, we find that .t  [ln (.5)/ ln (1 v)] tr d
This means that a dominant mutation that is gener-td
ations old will result in approximately the same marker
allele frequencies in the cases and controls as are seen
for a recessive mutation that is older by ln (.5)/
generations. For a tight ( ) screen,[ln(1 v)] v  .005
. For a looser ( ) screen,t  138 t v  .025 t  27r d r
. In practical terms, this means that a dominant mu-td
tation of a specified age will exhibit the LD character-
istics of an older recessive mutation, and this will be
reflected by increased sample size requirements for de-
tection of LD for dominant diseases.
Parameter Values Considered
To determine the test’s power on the basis of X2, one
must specify the age, in generations (t), of the mutation,
the recombination fraction (v) between the marker locus
and the disease locus, the disease-mutation frequency (r),
the marker allele frequencies (s), the number of cases
sampled (n), and the mode of inheritance of the disease.
Of these parameters, only v, s, and n can be controlled
by the investigators, so we focus on the effect that these
quantities have on the power to detect LD. Throughout,
we assume that an equal number of cases and controls
are sampled.
In the results presented here, we have assumed a rare-
mutation frequency of . This corresponds tor  .0025
a mutation on a single chromosome in an initial pop-
ulation of 200 people. Because r affects the vectors x
and y only through the term , small changes inr/ (1 r)
r do not change the results noticeably. We considered
fully penetrant recessive disease and dominant disease
with no phenocopies, recombination fractions consistent
with 1-, 2-, 5-, and 10-cM genome screens (i.e., v 
, .01, .025, and .05), and markers with 10 alleles..005
Results
Optimal Allele Frequency Configuration
Under the assumption that (i.e., the mu-r/ (1 r)  0
tation is rare), one can show, for a recessive disease, that
m 2s  ai2G (t)  c ,
a si1 i
where andt t ta  (1 v) / [2 (1 v) ] c  a(1 v) (1
. Maximizing with respect to , subject2a)(ma 1) G (t) s
to the constraint that , and holding v, t, and m s  1i
constant yields . Thus, for a recessive diseases  s Gi,ji j
and a fixed number of alleles, markers whose alleles are
equifrequent will be most powerful for detection of LD.
Since a dominant disease behaves like an older recessive
disease, this also applies to dominant diseases. For this
reason, our investigations focused primarily on com-
parison of multiallelic and diallelic markers with equi-
frequent alleles.
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Sample Size Requirements
For both recessive disease and dominant disease mod-
els, the use of multiallelic markers allows a substantial
drop in sample size, relative to that neededwhen diallelic
markers are used. Tables 2 and 3 show the number of
cases needed to achieve 80% power with a type I error
rate of 0.1%, for a fully penetrant recessive disease and
a fully penetrant dominant disease, respectively. We as-
sumed that all markers had equifrequent alleles. Figure
1 shows the required sample size for a multiallelic
marker, as a percentage of the sample size required for
a diallelic marker, for selected values of t and different
marker spacings. In the recessive disease case, most of
the drop in sample size of multiallelic markers relative
to diallelic markers is achieved by markers with six or
more alleles, and the sample sizes then required are
40%–60% of the diallelic sample sizes. In the dominant
disease case, most of the benefit is achieved by markers
with eight or more alleles, and the sample sizes required
are 30%–45% of the diallelic sample sizes. It is inter-
esting to note that the effect of the use of multiallelic
markers is more pronounced when the association is
weaker—that is, for older mutations or looser marker
screens. This effect is demonstrated in figure 2, for the
recessive disease example with a six-allele marker. In
light of this observation, it is not surprising that the effect
of multiallelic markers is more pronounced in applica-
tions to a dominant disease than in those to a recessive
disease, since a dominant mutation can be likened to an
older recessive mutation. These results clearly show that
there is a substantial benefit to the use of multiallelic
markers, rather than diallelic markers, in the search for
LD.
The sample sizes required for detection of LD inmore-
complex situations can be approximated by considera-
tion of the proportion of case chromosomes expected to
carry the mutation, a quantity that depends on the ge-
netic model. In the dominant disease example, only one-
half of the case chromosomes would be expected to carry
the mutation (see eq. [4]), and this results in sample sizes
that are increased relative to those required by the re-
cessive disease case. Figure 3 shows the sample size re-
quired in order to achieve 80% power when a  .001
(for a mutation age of and a screen density of 5t  20
cM) with six-allele markers, as a function of the fraction
of case chromosomes expected to carry the mutation.
For example, when the mixture fraction is equal to 1,
all of the case chromosomes are expected to carry the
mutation. This is equivalent to a recessive disease, and
the corresponding sample size is 24, as shown in table
2. The situation in which the mixture fraction is equal
to corresponds to a dominant disease, and the cor-12
responding sample size is 80 (see table 3). Other mixture
fractions can be observed as a result of more-complex
models of inheritance. Consider the dominant disease
case, with the added complication that there is a second
locus, unlinked to the first, that can cause the same phe-
notype. The resulting mixture fraction depends on the
population prevalence of disease caused by the second
mutation, relative to the prevalence of disease caused by
the dominant mutation, which is linked to our marker.
If the two types of disease are equally prevalent, then
the probability that a sampled case has disease caused
by the mutation linked to our marker is , and, even12
then, only one of the case’s two chromosomes will be
carrying the mutation. Therefore, the mixture fraction
in this example is , and the corresponding required1∼ 4
sample size is 262. It should also be noted that this
calculation assumes that the sample of control chro-
mosomes remains pure (see eqs. [3] and [4]). This as-
sumption will hold as long as the disease is rare. This
example demonstrates that, for complex diseases, sam-
ple sizes required for detection of LD may be unrealist-
ically large, because the mixture fraction will be quite
low.
Relative Spacings Required in Order to Achieve
Equivalent Power
The use of diallelic markers requires much denser
marker spacing—and, therefore, more markers—to
achieve the same power as is seen in a screen that uses
multiallelic markers. Figure 4 shows the marker spacing
required in order to achieve 80% power when a 
for a single test, as a function of the available sam-.001
ple size and the number of marker alleles, for a mod-
erately old mutation ( ). For example, when 100t  40
cases are available, the disease is recessively inherited,
and diallelic markers are to be used, marker spacing
must be4.48 cM to achieve adequate power; if 6-allele
markers were to be used, spacing of 6.53 cM would
be adequate. In this example, use of diallelic markers
requires 46% more markers than is required by use of
6-allele markers; if 10-allele markers were used, spacings
6.975 cM would have adequate power. The same pat-
tern is apparent for a dominantly inherited disease, and
the power difference between the use of diallelic markers
and the use of multiallelic markers is even more pro-
nounced. When 100 cases are available, the required
spacings are 1.065 cM, 3.44 cM, and 3.61 cM, for 2-,
8-, and 10-allele markers, respectively. The use of dial-
lelic markers, rather than 8-allele markers, for
a dominant disease requires 223% more markers to
achieve the same power. For both models of inheritance,
most of the benefit of the use of multiallelic markers is
achieved by use of markers with a moderate number of
alleles (i.e., or ). The use of markers withm  6 m  8
many alleles ( ) offers relatively little additionalm  10
improvement in either case.
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Table 2
No. of Cases Required in Order to Achieve 80% Power, When , for a Rare Recessive Diseasea  .001
m
NO. OF CASES REQUIRED, FOR MARKER SPACING OF
1 cM 2 cM 5 cM 10 cM
t  10 t  20 t  40 t  100 t  150 t  10 t  20 t  40 t  100 t  150 t  10 t  20 t  40 t  10 t  20 t  40
2 15 17 22 43 73 17 22 34 123 343 24 43 125 44 128 1,025
3 12 13 16 30 50 13 16 25 82 217 18 32 83 31 85 626
4 11 12 15 26 42 12 15 22 68 173 16 27 69 27 71 483
5 10 11 14 25 39 11 14 20 61 151 15 25 62 25 63 410
6 10 11 14 24 37 11 14 20 57 138 15 24 58 24 59 365
7 10 11 13 23 36 11 13 20 55 129 15 23 56 24 57 335
8 10 11 13 23 35 11 13 19 53 123 15 23 54 24 55 313
9 10 11 14 23 35 11 14 19 52 119 15 23 53 23 54 297
10 10 11 14 23 35 11 14 19 52 116 15 23 52 23 54 285
Table 3
No. of Cases Required in Order to Achieve 80% Power, When , for a Rare Dominant Diseasea  .001
m
NO. OF CASES REQUIRED, FOR MARKER SPACING OF
1 cM 2 cM 5 cM 10 cM
t  10 t  20 t  40 t  100 t  150 t  10 t  20 t  40 t  100 t  150 t  10 t  20 t  40 t  10 t  20 t40
2 71 79 98 181 302 79 98 148 503 1,382 109 183 511 186 525 4,111
3 48 54 66 118 192 54 66 98 314 837 73 120 319 121 327 2,440
4 42 46 55 97 154 46 55 80 247 642 61 97 251 99 257 1,836
5 38 42 50 86 135 42 50 72 213 541 55 86 216 88 221 1,520
6 36 40 47 79 123 40 47 67 193 479 52 80 195 81 200 1,324
7 35 38 45 75 116 38 45 64 179 437 50 76 181 77 186 1,190
8 35 38 44 73 111 38 44 62 170 407 48 73 172 74 176 1,093
9 34 37 44 71 107 37 44 61 163 385 48 72 165 72 168 1,019
10 34 37 43 70 104 37 43 60 158 367 47 70 161 71 163 961
The number of markers required is an important part
of the cost of conducting a study. Figure 5 shows the
number of diallelic markers required in order to achieve
80% power when , divided by the number ofa  .001
multiallelic markers required, as a function of the num-
ber of cases available, for the example in which t 
. For the recessive disease case, the multiallelic marker40
has six alleles; for the dominant disease case, the mul-
tiallelic marker has eight alleles. The use of diallelic
markers requires substantially more genotyping to
achieve the same power as is given by the multiallelic
markers, particularly for dominant diseases and small
sample sizes. Note that, as the sample size n increases,
the ratio of the number of diallelic to the number of
multiallelic markers appears to reach an asymptote; this
occurs relatively quickly for a recessive disease (n 
, ) but more slowly for a dominant disease,75 ratio  1.5
or, analogously, for an older recessive disease.
Feasibility of LD Testing
The results graphed in figure 6 are useful for deter-
mining when LD testing is a reasonable approach to
disease-gene localization, for a recessive disease. Re-
quired sample size is shown for young ( or 20),t  10
moderately old ( ), and old ( ) mutations,t  40 t  100
for the four screening densities considered, for 80%
power, and a testwise . For the tighter screensa  .001
(1 and 2 cM), the sample sizes required for detection of
LD with a recessive disease are reasonable for all four
ages of mutation, for both diallelic and six-allele mark-
ers. However, the use of six-allele markers always allows
a reduction in sample size, compared with that required
when diallelic markers are used. For example, when the
disease mutation is old ( ) and a 2-cM screen ist  100
used, use of six-allele markers reduces the sample size
from to , a reduction that is of practicaln  123 n  57
use for a rare recessive disease, for which sampling of
cases can be difficult. For a 5-cM screen, diallelic mark-
ers can detect LD by use of reasonable sample sizes for
only the two younger mutations. For a moderately old
mutation ( ), the required diallelic sample size oft  40
is reduced to when six-allele markersn  125 n  58
are used, again demonstrating that the use of multiallelic
markers is quite beneficial in this context. For the oldest
mutation, LD is not detectable with a reasonable sample
size, regardless of the number of marker alleles used.
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Figure 1 Sample size required in order to achieve 80% power when , as a percentage of sample size needed in order to achievea  .001
the same power for a diallelic marker. Sample sizes are shown for two screening densities (2 cM and 5 cM) and two mutation ages (t  20
and ). A, Recessive disease. B, Dominant disease.t  40
Table 4
No. of Cases Required in Order to Achieve 80% Power to Detect
LD, When , for Recessive Disease, for anda  .001 m  2 m  6
t
NO. OF CASES REQUIRED ( / ),M  2 M  6
FOR MARKER SPACING OFa
1 cM 2 cM 5 cM 10 cM
10    
20    128/59
40   125/58 
100  123/56  
a A minus sign () denotes that, for both values of m, !100 cases
were required; a plus sign () denotes that, for both values ofm, 1300
cases were required.
Finally, for the least-dense screen (10 cM), LD is de-
tectable with reasonable sample sizes only for the
younger mutations, and sample sizes are substantially
reduced by use of multiallelic markers (e.g., ,t  20
for diallelic markers vs. for six-allelen  128 n  59
markers).
Figure 7 shows similar results for a dominant disease,
comparing diallelic markers to eight-allele markers. For
a 1-cM screen, LD is detectable for all four ages of mu-
tation, and sample sizes are considerably smaller for the
multiallelic markers. For a 2-cM screen, LD is detectable
for all four ages of mutation with eight-allele markers,
but with diallelic markers and the oldest mutation, the
required sample size is prohibitively large ( ),n  503
even for this dense a screen. When a 5-cM screen is used,
detection of LD by use of diallelic markers is feasible
only for younger mutations. The use of eight-allelemark-
ers makes detection possible for the moderately old mu-
tation ( ), but the sample size remains unrealisti-t  40
cally large for the oldest mutation. For the loose screen
(10 cM) and with diallelic markers, LD is detectable only
for the very youngest mutation, and, even here, sample
sizes are quite large ( ). Use of eight-allele mark-n  186
ers makes detection of LD possible with the second
youngest mutation, but sample sizes remain prohibi-
tively large for the two older mutations.
Tables 4 and 5 show the above information in a dif-
ferent way. In table 4 for recessive disease, a minus sign
(“”) denotes a situation in which sample sizes were
!100 for both diallelic and six-allele markers, and a plus
sign (“”) denotes a situation in which both sample
sizes were greater than 300. Other cells contain the dial-
lelic sample size, followed by the six-allele sample size.
Those cells with numeric entries represent situations in
which the use of multiallelic markers may make LD test-
ing possible. Similar information for a dominant disease
is displayed in table 5. In this case, diallelic markers are
being compared to eight-allele markers, and aminus sign
(“”) denotes sample sizes less than 150 and a plus sign
(“”) denotes sample sizes greater than 300. Numeric
entries represent situations in which the use of multial-
lelic markers makes LD testing possible.
Markers with Nonequifrequent Alleles
All of the above results are for markers with equifre-
quent alleles. In order to investigate the performance of
this test when used with markers that are more typically
available, we considered the markers used in theGAW10
simulated data set (MacCluer et al. 1997), which were
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Figure 2 Sample size required in order to achieve 80% power
to detect LD with a recessive disease, when and a six-allelea  .001
marker is used, as a percentage of sample size needed in order to
achieve the same power for a diallelic marker, as a function of time
and marker-screening density.
Figure 3 Sample size required in order to achieve 80% power
to detect LD , when , for screen density 5 cM, , anda  .001 t  20
six-allele markers, as a function of the fraction of case chromosomes
expected to carry the linked mutation.
a random sample from the Research Genetics (Coop-
erative Human Linkage Consortium) mapping panels.
Figure 8 shows a histogram of the sample size required
in order to achieve 80% power when , for aa  .001
recessive mutation with , when using a 5-cMt  40
screen density. Themarkers selected are the 104 six-allele
markers in the GAW10 data set, which have a mean
heterozygosity of 0.75. The vertical lines denote the re-
quired sample sizes with use of the ideal equifrequent
six-allele marker, and the ideal equifrequent diallelic
marker. Because the markers sampled from a real map-
ping panel do not have equifrequent alleles, none of them
achieve the minimal sample size required by the ideal
six-allele marker. On average, these markers require a
sample size of about 70, a 17% increase above the min-
imal sample size of 59. While the real markers require
larger sample sizes than the ideal considered in this pa-
per, it is important to note that even these more realistic
sample sizes are much smaller than that required by the
best diallelic marker. The results for mutations of dif-
ferent ages and markers with different numbers of alleles
were very similar and are not presented here.
The heterozygosity of a marker is closely related to
the value of G2(0) and therefore to the power of the test
based on that marker. Examination of the GAW10mark-
ers indicates that, for a fixed number of marker alleles,
the relationship between heterozygosity andG2(0) is ap-
proximately linear ( for the six-allele markers,r  .992
recessive disease) and increasing, and it is therefore not
unreasonable to use heterozygosity to chose between
markers with the same number of alleles. Choosing be-
tween markers with different numbers of alleles is not
as simple, because the number of alleles affects the df
of the test statistic. For example, consider a four-allele
marker with equifrequent alleles and a six-allele marker
with four equifrequent alleles and two very rare alleles.
The two have similar heterozygosities and values of
G2(0), but the test based on the former has 3 df, whereas
the test based on the latter has five. Clearly, the former
marker will yield a more powerful test. When choosing
between markers with the same heterozygosity and dif-
ferent numbers of alleles, the one with fewer alleles will
be more powerful.
In determining the sample size required for a genome
screen, several approaches are possible. One is to cal-
culate the sample size needed for the desired power for
each marker in the panel, and then take the maximum
of these as the target sample size. Any mapping panel
will contain some suboptimal markers, and therefore
this approach might yield quite large sample sizes and
expensive studies. An alternative is to choose the sample
size so that the average power over all markers in the
panel is greater than or equal to the desired power.
Discussion
In this paper, we consider the utility of single-marker
LD testing that uses a case-control study design with
either diallelic or multiallelic markers. We focus pri-
marily on an initial genome screen for a disease locus
of interest, although the issues raised are also relevant
to localization of a previously mapped gene. We use a
deterministic population genetic model, ignoring genetic
drift, to calculate the expected marker allele frequencies
in the cases and controls, as a function of the marker
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Figure 4 Maximum possible marker spacing to achieve 80% power to detect LD with a mutation of age when , as at  40 a  .001
function of sample size and number of marker alleles. A, Recessive disease. B, Dominant disease.
Figure 5 Number of diallelic markers required for a genome
screen (80% power and ), relative to number of multiallelica  .001
markers required, as a function of available sample size. In the recessive
disease case the multiallelic marker has six alleles, whereas in the
dominant disease case it has eight alleles.
density, the age of the mutation, the number of marker
alleles, and the mode of inheritance of a rare disease of
monophyletic origin. This allows us to compare diallelic
markers to multiallelic markers in terms of sample sizes
required for detection of LD, by use of single-marker
tests, and to describe the relative marker spacings nec-
essary for diallelic markers to achieve the same power
as is given by multiallelic markers. Finally, we describe
the genetic models and population histories under which
LD can be detected by use of a single marker, with rea-
sonable sample sizes and marker densities.
In the situations considered here, multiallelic markers
always offer an improvement over diallelic markers un-
der otherwise equivalent conditions, in terms of power
to detect LD. This improvement in power is achieved by
moderately polymorphic markers (six to eight alleles),
suggesting that it is not necessary to go to great lengths
to obtain extremely polymorphic markers. It is impor-
tant to note that all the results presented here used a
Type I error level of for each test in a genomea  .001
screen. The overall Type I error rate for the genome
screen is related to the number of tests performed and
therefore depends on the screen density used. Our results
show that use of diallelic markers rather thanmultiallelic
markers requires a denser screen to achieve the same
power with a fixed sample size and a specific testwise
Type I error. Since more significance tests are performed
in the denser screen, the overall Type I error of that
screen is larger than for the less dense screen that is
possible with multiallelic markers. One could correct the
testwise Type I error to make the genome-wide Type I
errors comparable. This would further decrease the
power of tests that use diallelic markers for a given
screening density, or it would require an even denser
map of diallelic markers to retain the same power. These
considerations show conclusively that the use of diallelic
markers requires much denser screens and therefore
more genotyping to achieve the same power as is given
by a less-dense screen with use of multiallelic markers.
Recent technological developments (Chee et al. 1996)
suggest that it may soon be possible to type diallelic
markers quickly and inexpensively, making it more cost
effective to use very dense screens of diallelic markers,
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Figure 6 Sample size required in order to achieve 80% power to detect LD with a recessive mutation, when , as a function ofa  .001
screen density and age of mutation, for diallelic (A) and six-allele (B) markers.
Table 5
No. of Cases Required in Order to Achieve 80% Power to Detect
LD, When , for Dominant Disease, for anda  .001 m  2 m  8
t
NO. OF CASES REQUIRED (FOR
/ ), FOR MARKER SPACING OFam  2 m  6
1 cM 2 cM 5 cM 10 cM
10    184/74
20   183/73 525/176
40   511/172 
100 181/73 503/170  
a A minus sign () denotes that, for both values of m, !150 cases
were required; a plus sign () denotes that, for both values ofm, 1300
cases were required.
rather than more widely spaced screens of multiallelic
markers. We can speculate on the conditions under
which a screen with diallelic markers may be more cost
effective than a screen with multiallelic markers. Our
results suggest that, for detection of LD, diallelicmarkers
may become useful sooner with recessive diseases than
with dominant or complex diseases. This is because the
difference in required marker density, for diallelic mark-
ers versus multiallelic markers, is not as great for a re-
cessive disease as it is for a dominant disease. To achieve
equivalent overall cost for a sample of casesn  100
and a mutation age of , the per-genotype cost fort  40
a diallelic marker would need to be 64% of the per-
genotype cost for a 10-allele marker, when a recessive
disease is being analyzed; for a dominant disease, the
per-genotype cost for a diallelic marker would have to
be 29% of the per-genotype cost for a 10-allele mul-
tiallelic marker; for a more complex disease, for which
the proportion of the disease chromosomes in the cases
is !50%, which corresponds to a dominant disease, the
relative cost of the diallelic marker would have to be
even lower. Regardless of the cost of genotyping, at this
point in time, accurate maps are available only to a
resolution of 10 cM (Yuan et al. 1997). Improved res-
olution requires that either more families must be typed
for the current mapping panels or methods such as sperm
typing (Arnheim 1991) must be used to increase the
number of sampled meioses. With the mapping panels
currently available, 10-cM screens with multiallelic
markers are the only option. More-dense screens with
diallelic markers must wait for an improvement in map
resolution.
We have shown that, even in the ideal case of a fully
penetrant recessive disease caused by a single mutation,
a 10-cM genome screen does not have reasonable power
to detect LD unless the mutation under consideration is
very recent—that is, or 20. Even when the mu-t  10
tation is this recent, LD with a dominant mutation is
detectable in a 10-cM screen with reasonable sample
sizes only if multiallelic markers are used. If a 5-cM
screen is used, LD with a recessive mutation is detectable
by use of reasonable sample sizes even when a mutation
is moderately old ( ), with either type of marker;t  40
at this screening density, LD with a dominant mutation
of the same age is detectable only if multiallelic markers
are used. It is worth noting that sample sizes required
for detection of LD with a dominant mutation are quite
large. However, for a given disease-allele frequency, a
dominant disease is much more prevalent in the popu-
1882 Am. J. Hum. Genet. 63:1872–1885, 1998
Figure 7 Sample size required in order to achieve 80% power to detect LD with a dominant mutation, when , as a function ofa  .001
screen density and age of mutation, for diallelic (A) and eight-allele (B) markers.
lation than is a recessive disease, so collecting the larger
number of cases may not be a major problem.
The foregoing summary shows that, in the assessment
of the feasibility of genome screens for LD, it is very
important to consider the expected age of a mutation,
conditional on its existence in the current population.
Factors such as selection, rate of population growth, and
current disease-allele frequency will affect the expected
age of a mutation and, consequently, the expected size
of the region with detectable LD. Theoretical consid-
erations predict that mutations will be relatively young
both in populations that have undergone rapid and
steady population growth (Thompson and Neel 1997)
and in very small stable populations (Ewens 1979, p.
166). The latter, however, are unlikely to be useful for
the sorts of case-control studies considered here, pre-
cisely because of the small population size. In popula-
tions that have experienced a slower growth rate, mu-
tations are expected to be somewhat older. However,
because of the overall population growth in the human
species, the age of few mutations would be expected to
be 150 generations, and the age of many mutations
will be younger than 40–80 generations (Thompson and
Neel 1997). Although our calculations do not allow for
an increase in mutation frequency, we do not expect that
such a scenario would change our results substantially,
as long as the mutation is still rare and monophyletic.
Since the sampled chromosomes are still removed from
the ancestral chromosome by the same number of mei-
oses, the observable patterns of single-locus disequilibria
should be similar.
A growing body of data supports these general the-
oretical predictions about the likely ages of mutations
existing in human populations. In cases in which there
is evidence of monophyletic mutation, the sizes of ge-
nomic regions with evidence of LD are generally 5–12
cM in populations that have experienced recent, rapid
population growth and that, therefore, may be expected
to have young disease mutations. Such populations often
are composed of relatively recent ( ) immigrantst  40
into environments that then allow rapid population
growth. They are also generally populations without sig-
nificant gene flow from other populations, thereby re-
taining the monophyletic origin of rare disease muta-
tions. Examples include diseases showing strong founder
effects in French Canadians (Casaubon et al. 1996), Ash-
kenazi Jews (Risch et al. 1995), Roma (Kalaydjieva et
al. 1996), Volga Germans (Bird et al. 1988), and the
Amish (Sulisalo et al. 1994). The Finns, with a somewhat
older initial immigration time ( ), also show80 ! t ! 100
evidence of founder effects through large regions of LD
around disease loci (Varilo et al. 1996), possibly because
of both a history of extremely rapid population growth
and additional recent migration, within the past 20 gen-
erations, into the northern parts of the country (Norio
1991). Ages of mutations in some of these populations
have been estimated to be between (Risch et al.t  14
1995) and (Varilo et al. 1996), although ex-t  20–30
treme caution must be used in the interpretation of such
estimates, since their variance is enormous. These ob-
servations of extended regions of LD are consistent with
young mutation age and suggest that a 10-cM genome
screen for LD, with use of multiallelic markers, may be
a reasonable way to approach the localization of Men-
delian disease genes in populations such as these.
Some authors (Risch and Merikangas 1996; Brown
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Figure 8 Sample sizes required in order to achieve 80% power
to detect LD with a recessive mutation, when , for a 5-cMa  .001
screen when , for the six-allele GAW10 markers.t  40
and Hartwell 1998) have suggested the use of LD screen-
ing methods in large randomly mating populations that
are not genetic isolates. There is evidence that LD is
detectable near Mendelian disease loci in such popula-
tions. When analysis is restricted to members of reason-
ably well-defined ethnic or political groups, evidence of
LD can frequently be found with markers spanning the
disease loci at 0.5–1.4-cM intervals (Wijsman 1997).
Examples are found in the Japanese (Goddard et al.
1996), Italians (Pandolfo et al. 1990), British (Votruba
et al. 1998), and Poles (Brzustowicz et al. 1993). These
small intervals of detectable LD suggest older mutations,
the existence of multiple mutations combined with ad-
mixture, or both, thereby inhibiting detection of LD,
relative to the situation in isolated populations. Genome
screens at the currently available density of 10 cM are
clearly not adequate for detection of such LD, with rea-
sonable sample sizes, but the existence of LD at small
recombination fractions does suggest that, with a much
denser map, especially of multiallelic markers, detection
of LDwith simple genetic diseases might be possible even
in these nonisolated populations.
Even though our evaluation is based on highly opti-
mistic conditions, some general extrapolation to more-
complicated scenarios is possible. The results presented
here are for fully penetrant recessive diseases and dom-
inant diseases, but the methods used to calculate power
can be easily applied to either diseases with reduced pen-
etrance or more-complex models of inheritance. Com-
parison of conditions necessary to detect LDwith a dom-
inant versus recessive mutation provides insight into the
effects of “contamination” of the sample of chromo-
somes available in the case population. For the param-
eters considered here, the dominant disease case required
a 3.5–4.5-fold increase in sample size, compared with
the recessive disease case. Clearly, this implies that, for
mild contamination of the disease chromosomes, such
as may occur because of a rare additional unlinked dis-
ease mutation, the sample size requirements will gen-
erally remain tolerable. However, this also suggests that
a smaller sample of cases selected from a restricted pop-
ulation thought to be more homogeneous with respect
to disease mutation may provide more power than is
given by analysis of a larger but more heterogeneous
sample. These results also suggest that, as the mixture
fraction increases, as would be expected for a more com-
plex trait, the sample sizes required may become ex-
tremely large.
LD testing as a fine-scale gene localization tool is well
established, but LD testing as a genome screening tool
has not yet been used to successfully map a disease gene.
The results that we have presented here should further
aid in the design of efficient studies aimed at fine-scale
localization, but they raise questions about the feasibility
of the use of single-marker LD testing in genome screens
with anonymous markers. In a case-control design, LD
is quickly obscured by even small complications, such
as increasing mutation age and dominance. When added
complications, such as multiple susceptibility loci and
sporadic cases, are included, the required sample sizes
and marker densities increase rapidly. In addition, as the
difficulty in the detection of LD increases, so does the
penalty inherent in the use of diallelic markers, as com-
pared with the use of multiallelic markers. Together,
these considerations suggest that the promise of diallelic
markers for LD screens may be difficult to achieve.How-
ever, we have considered only single-marker tests here,
and it is possible that future work onmultipointmethods
and methods that use haplotypes could change this pic-
ture. Until such studies have been performed, care should
be taken to avoid overstatement of the potential of LD
screening as a gene mapping tool, particularly in the case
of complex traits.
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